Researchers have developed a new experimental molecule that could offer a promising treatment option for aggressive Triple-Negative Breast Cancer, a form of breast cancer that currently has limited targeted therapies.
The molecule, called SU212, works by targeting and breaking down an enzyme known as ENO1 (enolase 1). Cancer cells often produce large amounts of this enzyme to support their rapid growth by increasing glucose metabolism. By disabling ENO1, the new compound was able to slow tumor growth and reduce the spread of cancer in laboratory mouse models.
Researchers say the discovery could have broader implications beyond triple-negative breast cancer. ENO1 is also linked to several other cancers, including Glioma, Pancreatic Cancer, and Thyroid Cancer, raising the possibility that the same strategy could be used to treat multiple tumor types.
Scientists also note that the approach may be particularly relevant for cancer patients with metabolic conditions such as Diabetes, since the therapy targets cancer’s dependence on glucose metabolism.